Date: 2023-10-10 Your Name: Xia Lu

Manuscript Title: Preoperative Metabolic Parameters of 18F-FDG PET/CT is Associated with TNM Stage

and Prognosis of Colorectal Cancer Patients
Manuscript number (if known): QIMS-23-966-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (Nos: 82272034, 82001861, 82102088, and 82001860) Capital's Funds for Health Improvement and Research (No. 2020-2-2025) National Key Research and Development Plan	

		(No: 2020YFC0122000)	
		Time frame: pas	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
	_		
7	Support for attending	√None	
	meetings and/or travel		
0	Detents planned incored	(Mana	
8	Patents planned, issued	√None	
	or pending		
	Double in a time and a Date	(Alama	
9	Participation on a Data	√None	
	Safety Monitoring Board or Advisory Board		
10		(Name	
10	Leadership or fiduciary	√None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
11	unpaid Stock or stock options	√None	
11	Stock of Stock options	* INUTIE	
10	Pagaint of aguinment	./None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
10	writing, gifts or other services	√None.	
13	writing, gifts or other	√None	

This study was funded by the National Natural Science Foundation of China (Nos. 82272034, 82001 82102088, and 82001860), Capital's Funds for Health Improvement and Research (No. 2020-2-2025 National Key Research and Development Plan (No. 2020YFC0122000).	•

Please place an "X" next to the following statement to indicate your agreement:

Date: 2023-10-10

Your Name: Guanyun Wang

Manuscript Title: Preoperative Metabolic Parameters of 18F-FDG PET/CT is Associated with TNM Stage

and Prognosis of Colorectal Cancer Patients
Manuscript number (if known): QIMS-23-966-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	National Natural Science Foundation of China (Nos: 82272034, 82001861, 82102088, and 82001860)	
	charges, etc.)	Capital's Funds for	
	No time limit for this	Health Improvement	
	item.	and Research (No. 2020-2-2025)	
		National Key Research and Development Plan	

		(No: 2020YFC0122000)	
		Time frame: pas	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
	_		
7	Support for attending	√None	
	meetings and/or travel		
0	Detents planned incored	(Mana	
8	Patents planned, issued	√None	
	or pending		
	Double in a time and a Date	(Alama	
9	Participation on a Data	√None	
	Safety Monitoring Board or Advisory Board		
10		(Name	
10	Leadership or fiduciary	√None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
11	unpaid Stock or stock options	√None	
11	Stock of Stock options	* INUTIE	
10	Pagaint of aguinment	./None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
10	writing, gifts or other services	√None.	
13	writing, gifts or other	√None	

This study was funded by the National Natural Science Foundation of China (Nos. 82272034, 82001 82102088, and 82001860), Capital's Funds for Health Improvement and Research (No. 2020-2-2025 National Key Research and Development Plan (No. 2020YFC0122000).	•

Please place an "X" next to the following statement to indicate your agreement:

Date: 2023-10-10

Your Name: Lijuan Feng

Manuscript Title: Preoperative Metabolic Parameters of 18F-FDG PET/CT is Associated with TNM Stage

and Prognosis of Colorectal Cancer Patients
Manuscript number (if known): QIMS-23-966-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (Nos: 82272034, 82001861, 82102088, and 82001860) Capital's Funds for Health Improvement and Research (No. 2020-2-2025) National Key Research and Development Plan	

		(No: 2020YFC0122000)	
		Time frame: pas	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
	_		
7	Support for attending	√None	
	meetings and/or travel		
0	Detents planned incored	(Mana	
8	Patents planned, issued	√None	
	or pending		
	Double in a time and a Date	(Alama	
9	Participation on a Data	√None	
	Safety Monitoring Board or Advisory Board		
10		(Name	
10	Leadership or fiduciary	√None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
11	unpaid Stock or stock options	√None	
11	Stock of Stock options	* INUTIE	
10	Pagaint of aguinment	./None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
10	writing, gifts or other services	√None.	
13	writing, gifts or other	√None	

This study was funded by the National Natural Science Foundation of China (Nos. 82272034, 82001 82102088, and 82001860), Capital's Funds for Health Improvement and Research (No. 2020-2-2025 National Key Research and Development Plan (No. 2020YFC0122000).	•

Please place an "X" next to the following statement to indicate your agreement:

Date: 2023-10-10 Your Name: Ying Kan

Manuscript Title: Preoperative Metabolic Parameters of 18F-FDG PET/CT is Associated with TNM Stage

and Prognosis of Colorectal Cancer Patients
Manuscript number (if known): QIMS-23-966-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (Nos: 82272034, 82001861, 82102088, and 82001860) Capital's Funds for Health Improvement and Research (No. 2020-2-2025) National Key Research and Development Plan	

		(No: 2020YFC0122000)	
		Time frame: pas	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
	_		
7	Support for attending	√None	
	meetings and/or travel		
0	Detents planned incored	(Mana	
8	Patents planned, issued	√None	
	or pending		
	Double in a time and a Date	(Alama	
9	Participation on a Data	√None	
	Safety Monitoring Board or Advisory Board		
10		(Name	
10	Leadership or fiduciary	√None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
11	unpaid Stock or stock options	√None	
11	Stock of Stock options	* INUTIE	
10	Pagaint of aguinment	./None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
10	writing, gifts or other services	√None.	
13	writing, gifts or other	√None	

This study was funded by the National Natural Science Foundation of China (Nos. 82272034, 82001 82102088, and 82001860), Capital's Funds for Health Improvement and Research (No. 2020-2-2025 National Key Research and Development Plan (No. 2020YFC0122000).	•

Please place an "X" next to the following statement to indicate your agreement:

Date: 2023-10-10 Your Name: Wei Wang

Manuscript Title: Preoperative Metabolic Parameters of 18F-FDG PET/CT is Associated with TNM Stage

and Prognosis of Colorectal Cancer Patients
Manuscript number (if known): QIMS-23-966-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (Nos: 82272034, 82001861, 82102088, and 82001860) Capital's Funds for Health Improvement and Research (No. 2020-2-2025) National Key Research and Development Plan	

		(No: 2020YFC0122000)	
		Time frame: pas	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	
	_		
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
	Bulling	ZNI	
8	Patents planned, issued	√None	
	or pending		
		l .	
_	D. P. C. C. D. C.	ZNI	
9	Participation on a Data	√None	
9	Safety Monitoring Board	√None	
	Safety Monitoring Board or Advisory Board		
9	Safety Monitoring Board or Advisory Board Leadership or fiduciary	√None ✓None	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board,		
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or		
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or		
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or		
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options	√None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment,	√None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical	√None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other	√None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None ✓None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other	√None ✓None	

This study was funded by the National Natural Science Foundation of China (Nos. 82272034, 82001 82102088, and 82001860), Capital's Funds for Health Improvement and Research (No. 2020-2-2025 National Key Research and Development Plan (No. 2020YFC0122000).	•

Please place an "X" next to the following statement to indicate your agreement:

Date: 2023-10-10

Your Name: Jigang Yang

Manuscript Title: Preoperative Metabolic Parameters of 18F-FDG PET/CT is Associated with TNM Stage

and Prognosis of Colorectal Cancer Patients
Manuscript number (if known): QIMS-23-966-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (Nos: 82272034, 82001861, 82102088, and 82001860) Capital's Funds for Health Improvement and Research (No. 2020-2-2025) National Key Research and Development Plan	

		(No: 2020YFC0122000)	
		Time frame: pas	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	
	_		
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
	Bulling	ZNI	
8	Patents planned, issued	√None	
	or pending		
		l .	
_	D. P. C. C. D. C.	ZNI	
9	Participation on a Data	√None	
9	Safety Monitoring Board	√None	
	Safety Monitoring Board or Advisory Board		
9	Safety Monitoring Board or Advisory Board Leadership or fiduciary	√None ✓None	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board,		
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or		
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or		
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or		
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options	√None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment,	√None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical	√None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other	√None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None ✓None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other	√None ✓None	

This study was funded by the National Natural Science Foundation of China (Nos. 82272034, 82001 82102088, and 82001860), Capital's Funds for Health Improvement and Research (No. 2020-2-2025 National Key Research and Development Plan (No. 2020YFC0122000).	•

Please place an "X" next to the following statement to indicate your agreement:

Date: 2023-10-10

Your Name: Mingyu Zhang

Manuscript Title: Preoperative Metabolic Parameters of 18F-FDG PET/CT is Associated with TNM Stage

and Prognosis of Colorectal Cancer Patients
Manuscript number (if known): QIMS-23-966-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (Nos: 82272034, 82001861, 82102088, and 82001860) Capital's Funds for Health Improvement and Research (No. 2020-2-2025) National Key Research and Development Plan	

		(No: 2020YFC0122000)	
		Time frame: pas	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	
	_		
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
	Bulling	ZNI	
8	Patents planned, issued	√None	
	or pending		
		l .	
_	D. P. C. C. D. C.	ZNI	
9	Participation on a Data	√None	
9	Safety Monitoring Board	√None	
	Safety Monitoring Board or Advisory Board		
9	Safety Monitoring Board or Advisory Board Leadership or fiduciary	√None ✓None	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board,		
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or		
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or		
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or		
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options	√None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment,	√None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical	√None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other	√None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None ✓None ✓None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other	√None ✓None	

This study was funded by the National Natural Science Foundation of China (Nos. 82272034, 82001 82102088, and 82001860), Capital's Funds for Health Improvement and Research (No. 2020-2-2025 National Key Research and Development Plan (No. 2020YFC0122000).	•

Please place an "X" next to the following statement to indicate your agreement: